Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis: A case report

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis : A case report. / Dalbjerg, Sara Maria; Tsakiri, Anna; Fredriksen, Jette Lautrup.

I: Multiple Sclerosis and Related Disorders, Bind 8, 07.2016, s. 93-95.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Dalbjerg, SM, Tsakiri, A & Fredriksen, JL 2016, 'Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis: A case report', Multiple Sclerosis and Related Disorders, bind 8, s. 93-95. https://doi.org/10.1016/j.msard.2016.05.005

APA

Dalbjerg, S. M., Tsakiri, A., & Fredriksen, J. L. (2016). Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 8, 93-95. https://doi.org/10.1016/j.msard.2016.05.005

Vancouver

Dalbjerg SM, Tsakiri A, Fredriksen JL. Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders. 2016 jul.;8:93-95. https://doi.org/10.1016/j.msard.2016.05.005

Author

Dalbjerg, Sara Maria ; Tsakiri, Anna ; Fredriksen, Jette Lautrup. / Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis : A case report. I: Multiple Sclerosis and Related Disorders. 2016 ; Bind 8. s. 93-95.

Bibtex

@article{7fdccfb11bdf4df4abcb39c618f7dc33,
title = "Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis: A case report",
abstract = "Background Multiple sclerosis is an inflammatory disease of the central nervous system for which there is currently no cure. Interferon-beta-1-alpha is worldwide one of the most widely used treatments in multiple sclerosis. To our knowledge there is one previous reported case of rhabdomyolysis associated with Interferon-beta treatment. Case presentation We describe a 30 year old man with relapsing remitting multiple sclerosis who developed rhabdomyolysis and increased creatine kinase following Interferon-beta-1-alpha therapy. After the medication was discontinued, the patient rapidly improved. Conclusion Clinicians should be aware of the possibility of rhabdomyolysis occurring during Interferon-beta-1-alpha therapy. In cases where patients complain of severe myalgia, and in particular if weakness is reported, creatine kinase activity should be measured to prevent irreversible rhabdomyolysis during Interferon-beta-1-alpha therapy in patients with multiple sclerosis.",
keywords = "Adverse effect, Interferon-beta treatment, Multiple sclerosis, Quality of life, Rhabdomyolysis",
author = "Dalbjerg, {Sara Maria} and Anna Tsakiri and Fredriksen, {Jette Lautrup}",
year = "2016",
month = jul,
doi = "10.1016/j.msard.2016.05.005",
language = "English",
volume = "8",
pages = "93--95",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis

T2 - A case report

AU - Dalbjerg, Sara Maria

AU - Tsakiri, Anna

AU - Fredriksen, Jette Lautrup

PY - 2016/7

Y1 - 2016/7

N2 - Background Multiple sclerosis is an inflammatory disease of the central nervous system for which there is currently no cure. Interferon-beta-1-alpha is worldwide one of the most widely used treatments in multiple sclerosis. To our knowledge there is one previous reported case of rhabdomyolysis associated with Interferon-beta treatment. Case presentation We describe a 30 year old man with relapsing remitting multiple sclerosis who developed rhabdomyolysis and increased creatine kinase following Interferon-beta-1-alpha therapy. After the medication was discontinued, the patient rapidly improved. Conclusion Clinicians should be aware of the possibility of rhabdomyolysis occurring during Interferon-beta-1-alpha therapy. In cases where patients complain of severe myalgia, and in particular if weakness is reported, creatine kinase activity should be measured to prevent irreversible rhabdomyolysis during Interferon-beta-1-alpha therapy in patients with multiple sclerosis.

AB - Background Multiple sclerosis is an inflammatory disease of the central nervous system for which there is currently no cure. Interferon-beta-1-alpha is worldwide one of the most widely used treatments in multiple sclerosis. To our knowledge there is one previous reported case of rhabdomyolysis associated with Interferon-beta treatment. Case presentation We describe a 30 year old man with relapsing remitting multiple sclerosis who developed rhabdomyolysis and increased creatine kinase following Interferon-beta-1-alpha therapy. After the medication was discontinued, the patient rapidly improved. Conclusion Clinicians should be aware of the possibility of rhabdomyolysis occurring during Interferon-beta-1-alpha therapy. In cases where patients complain of severe myalgia, and in particular if weakness is reported, creatine kinase activity should be measured to prevent irreversible rhabdomyolysis during Interferon-beta-1-alpha therapy in patients with multiple sclerosis.

KW - Adverse effect

KW - Interferon-beta treatment

KW - Multiple sclerosis

KW - Quality of life

KW - Rhabdomyolysis

U2 - 10.1016/j.msard.2016.05.005

DO - 10.1016/j.msard.2016.05.005

M3 - Journal article

C2 - 27456881

AN - SCOPUS:84970005869

VL - 8

SP - 93

EP - 95

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -

ID: 179222638